开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
Airbus CEO: production rate "at an appropriate pace".
2026-10-29
Airbus CEO: production rate "at an appropriate pace".
返回
其他消息
2026-10-28
EIA报告显示,美国中西部汽油库存上周降至历史低位。
EIA报告显示,美国中西部汽油库存上周降至历史低位。
2026-10-28
Jiangsu Hengrui Medicine Co., Ltd said its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd has received an approval notice from the National Medical Products Administration to begin clinical trials of HRS-2189 tablets and will start trials shortly. HRS-2189 is a novel KAT6 inhibitor that downregulates oncogene expression by inhibiting histone lysine acetylation and is being developed for advanced malignant tumors. No other KAT6-targeting drug is currently approved domestically or abroad. R&D
Jiangsu Hengrui Medicine Co., Ltd said its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd has received an approval notice from the National Medical Products Administration to begin clinical trials of HRS-2189 tablets and will start trials shortly. HRS-2189 is a novel KAT6 inhibitor that downregulates oncogene expression by inhibiting histone lysine acetylation and is being developed for advanced malignant tumors. No other KAT6-targeting drug is currently approved domestically or abroad. R&D investment in the HRS-2189 program to date totals about 55.3 mln yuan.
Chat with us
, powered by
LiveChat